Co-Authors
This is a "connection" page, showing publications co-authored by JASON B FLEMING and GIULIO DRAETTA.
Connection Strength
0.713
-
Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature. 2019 04; 568(7752):410-414.
Score: 0.168
-
In?Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Rep. 2016 06 28; 16(1):133-147.
Score: 0.138
-
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res. 2015 Mar 15; 75(6):1091-101.
Score: 0.127
-
PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nat Commun. 2021 07 30; 12(1):4626.
Score: 0.049
-
YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. JCI Insight. 2019 11 01; 4(21).
Score: 0.044
-
Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. Cancer Res. 2019 Nov 01; 79(21):5612-5625.
Score: 0.043
-
Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. Cell Rep. 2019 02 05; 26(6):1518-1532.e9.
Score: 0.042
-
Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature. 2017 02 16; 542(7641):362-366.
Score: 0.036
-
Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature. 2017 02 02; 542(7639):119-123.
Score: 0.036
-
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014 Oct 30; 514(7524):628-32.
Score: 0.030